Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Gentzler RD, Villaruz LC, Rhee JC, Horton B, Mock J, Hanley M, Kim K, Rudek MA, Phelps MA, Carducci MA, Piekarz R, Park KS, Bullock TN, Rudin CM. Gentzler RD, et al. Among authors: villaruz lc. Oncologist. 2023 Nov 2;28(11):1007-e1107. doi: 10.1093/oncolo/oyad221. Oncologist. 2023. PMID: 37555284 Free PMC article. Clinical Trial.
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.
Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Grady CB, et al. Among authors: villaruz lc. Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70049. doi: 10.1002/pds.70049. Pharmacoepidemiol Drug Saf. 2024. PMID: 39586662 Free PMC article.
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Fortman D, Wang H, VanderWeele R, Evans T, Herman JG, Rhee J, Reyes V, McLaughlin B, Wozniak A, Somasundaram A, Mekhail T, Socinski MA, Schulze K, Villaruz LC. Fortman D, et al. Among authors: villaruz lc. Clin Lung Cancer. 2025 Jan;26(1):78-81. doi: 10.1016/j.cllc.2024.10.014. Epub 2024 Oct 30. Clin Lung Cancer. 2025. PMID: 39578170 Free article.
Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
Altan M, Lopes G, Hiltermann TJN, Govindan R, Villaruz LC, Calvo E, Edelman MJ, Furqan M, Neal J, Felip E, Carlisle JW, Heymach JV, O'Cearbhaill RE, Zauderer M, Chisamore M, Corigliano E, Eleftheriadou I, Zajic S, Jenkins B, Goodison S, Suchindran S, Ramos-Hernandez N, Tarek N, Schoenfeld AJ. Altan M, et al. Among authors: villaruz lc. Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591. Online ahead of print. Clin Cancer Res. 2024. PMID: 39576208
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Mansfield AS, et al. Among authors: villaruz lc. Lung Cancer. 2024 Sep;195:107928. doi: 10.1016/j.lungcan.2024.107928. Epub 2024 Aug 13. Lung Cancer. 2024. PMID: 39197359 Clinical Trial.
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Munster P, et al. Among authors: villaruz lc. Cancer Res Commun. 2024 Mar 13;4(3):785. doi: 10.1158/2767-9764.CRC-24-0133. Cancer Res Commun. 2024. PMID: 38477691 Free PMC article. No abstract available.
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2.
Shaverdashvili K, Reyes V, Wang H, Mehta D, Marsh C, Waas JK, VanderWeele RA, Peracha SM, Liang H, Socinski MA, Gerber DE, Dowell JE, Villaruz LC. Shaverdashvili K, et al. Among authors: villaruz lc. EClinicalMedicine. 2023 Nov 21;66:102317. doi: 10.1016/j.eclinm.2023.102317. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192592 Free PMC article.
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Munster P, et al. Among authors: villaruz lc. Cancer Res Commun. 2023 Dec 19;3(12):2572-2584. doi: 10.1158/2767-9764.CRC-22-0461. Cancer Res Commun. 2023. PMID: 38115208 Free PMC article. Clinical Trial.
59 results